The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
ALK and EGFR mutation analysis in a phase II trial of cisplatin/pemetrexed in Japanese patients with advanced nonsquamous non-small cell lung cancer.
Kyohei Kaburaki
No relevant relationships to disclose
Fumiyoshi Ohyanagi
No relevant relationships to disclose
Azusa Tanimoto
No relevant relationships to disclose
Toshio Sakatani
No relevant relationships to disclose
Yuko Kawano
No relevant relationships to disclose
Ryota Saito
No relevant relationships to disclose
Noriko Yanagitani
No relevant relationships to disclose
Keita Kudo
No relevant relationships to disclose
Atsushi Horiike
No relevant relationships to disclose
Sachiko Hagiwara
No relevant relationships to disclose
Noriko Motoi
No relevant relationships to disclose
Kengo Takeuchi
No relevant relationships to disclose
Yuichi Ishikawa
No relevant relationships to disclose
Takeshi Horai
No relevant relationships to disclose
Makoto Nishio
No relevant relationships to disclose